• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

    1/10/23 12:37:35 PM ET
    $SWAV
    Medical/Dental Instruments
    Health Care
    Get the next $SWAV alert in real time by email
    SC 13G/A 1 tv0009-shockwavemedicalinc.htm SCHEDULE 13G/A shockwavemedicalinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 3)*

    Name of issuer:  Shockwave Medical Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  82489T104

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  82489T104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    60,758

    7.  SOLE DISPOSITIVE POWER

    3,598,702

    8.  SHARED DISPOSITIVE POWER

    96,229

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,694,931

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.22%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Shockwave Medical Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    5403 Betsy Ross Drive
    Santa Clara, CA 95054

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    82489T104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  January 10, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $SWAV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SWAV

    DatePrice TargetRatingAnalyst
    4/5/2024Outperform → Peer Perform
    Wolfe Research
    3/27/2024$368.00Buy
    CL King
    9/29/2023$218.00Neutral
    UBS
    7/10/2023$291.00 → $335.00Equal-Weight → Overweight
    Morgan Stanley
    5/30/2023$291.00Equal-Weight
    Morgan Stanley
    3/15/2023$240.00Buy
    Needham
    12/16/2022$285.00Buy
    Deutsche Bank
    12/12/2022$300.00 → $235.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $SWAV
    Financials

    Live finance-specific insights

    See more
    • Shockwave Medical Reports First Quarter 2024 Financial Results

      SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. "The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "Our team is looking forward to continuing our mission as part of Johnson & Johnson and to

      5/6/24 4:05:00 PM ET
      $JNJ
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Johnson & Johnson to Acquire Shockwave Medical

      Enhances Johnson & Johnson's Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech's Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ) and Shockwave Medical, Inc. (NASDAQ:SWAV) ("Shockwave") today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335

      4/5/24 6:31:00 AM ET
      $JNJ
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results

      SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2023. Recent Highlights Recognized revenue of $203.0 million for the fourth quarter of 2023 and $730.2 million for the full year 2023, representing increases of 41% and 49%, respectively, from the same periods in 2022Initiated the full U.S. commercial launch of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheterGranted new physician and hospital reimbursement for

      2/15/24 4:03:00 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    SEC Filings

    See more
    • SEC Form 15-12G filed by Shockwave Medical Inc.

      15-12G - Shockwave Medical, Inc. (0001642545) (Filer)

      6/10/24 4:33:25 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Shockwave Medical Inc.

      S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)

      5/31/24 4:38:18 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Shockwave Medical Inc.

      S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)

      5/31/24 4:28:57 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Francis Laura returned 4,784 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Shockwave Medical, Inc. (0001642545) (Issuer)

      5/31/24 4:42:11 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • Moll Frederic H returned 287,521 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Shockwave Medical, Inc. (0001642545) (Issuer)

      5/31/24 4:41:41 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • Papiernik Antoine returned 34,913 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Shockwave Medical, Inc. (0001642545) (Issuer)

      5/31/24 4:40:07 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SWAV
    Leadership Updates

    Live Leadership Updates

    See more
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

      SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

      10/28/24 7:00:00 AM ET
      $ISRG
      $PRCT
      $SNBR
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
      Home Furnishings
    • Sarepta Therapeutics Set to Join S&P MidCap 400

      NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For

      5/29/24 5:48:00 PM ET
      $JNJ
      $SPGI
      $SRPT
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

      SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

      10/28/24 7:00:00 AM ET
      $ISRG
      $PRCT
      $SNBR
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
      Home Furnishings
    • Sarepta Therapeutics Set to Join S&P MidCap 400

      NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For

      5/29/24 5:48:00 PM ET
      $JNJ
      $SPGI
      $SRPT
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance

    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ShockWave Medical downgraded by Wolfe Research

      Wolfe Research downgraded ShockWave Medical from Outperform to Peer Perform

      4/5/24 7:33:47 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • CL King initiated coverage on ShockWave Medical with a new price target

      CL King initiated coverage of ShockWave Medical with a rating of Buy and set a new price target of $368.00

      3/27/24 8:20:17 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on ShockWave Medical with a new price target

      UBS initiated coverage of ShockWave Medical with a rating of Neutral and set a new price target of $218.00

      9/29/23 7:46:27 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

      SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

      2/13/24 5:13:59 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

      SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

      2/9/24 9:49:30 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by ShockWave Medical Inc.

      SC 13G - Shockwave Medical, Inc. (0001642545) (Subject)

      2/8/24 10:17:35 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care